Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T19:58:26.352Z.
Calculation as of: 2026-10-06T19:58:26.352Z.
Quote observation: 2026-10-06T19:55:25.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 23d17170dcd90d56222e16e6e1c46ca5d6e49f0f5e08d353dc7d5f06f7b1586d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$9.67B
EV/EBITDA Ratio
45.27x
TTM Avg
45.64x
3Y Avg
58.48x
5Y Avg
58.48x
Market Cap
$9.66B
EV/EBITDA Ratio
12.25x
TTM Avg
11.82x
3Y Avg
11.96x
5Y Avg
11.68x
Market Cap
$9.88B
EV/EBITDA Ratio
67.08x
TTM Avg
66.53x
3Y Avg
81.35x
5Y Avg
68.10x
Market Cap
$9.93B
EV/EBITDA Ratio
27.76x
TTM Avg
22.27x
3Y Avg
19.88x
5Y Avg
21.50x
Market Cap
$10.03B
EV/EBITDA Ratio
20.65x
TTM Avg
24.30x
3Y Avg
24.10x
5Y Avg
21.70x
Market Cap
$9.21B
EV/EBITDA Ratio
30.68x
TTM Avg
23.19x
3Y Avg
21.87x
5Y Avg
21.39x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vaxcyte, Inc. (PCVX) | $9.66B | N/A | N/A | N/A | N/A |
| Krystal Biotech, Inc. (KRYS)vs › | $9.67B | 45.27x | 45.64x | 58.48x | 58.48x |
| Henry Schein, Inc. (HSIC)vs › | $9.66B | 12.25x | 11.82x | 11.96x | 11.68x |
| Repligen Corporation (RGEN)vs › | $9.88B | 67.08x | 66.53x | 81.35x | 68.10x |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.93B | 27.76x | 22.27x | 19.88x | 21.50x |
| Insulet Corp. (PODD)vs › | $9.33B | 15.68x | 28.49x | 45.32x | 85.61x |
| The Ensign Group, Inc. (ENSG)vs › | $10.03B | 20.65x | 24.30x | 24.10x | 21.70x |
| Bruker Corporation (BRKR)vs › | $9.21B | 30.68x | 23.19x | 21.87x | 21.39x |
| ImmunityBio, Inc. (IBRX)vs › | $10.12B | N/A | N/A | N/A | N/A |
| Align Technology, Inc. (ALGN)vs › | $10.13B | 11.35x | 14.07x | 18.68x | 23.02x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
